Genmab reaches Arzerra milestone payment  

2010.04.23
Danish biotech company Genmab has reached a lucrative milestone for its drug Arzerra as the European Commission gives conditional marketing approval in the EU

Danish biotech company Genmab has reached a lucrative milestone for its drug Arzerra as the European Commission gives conditional marketing approval in the EU, reports financial daily newspaper Børsen.

 

Arzerra (ofatumumab), which Genmab has developed under a collaborative agreement with GlaxoSmithKline, has been given the authorization for the treatment of refractory chronic lymphocytic leukemia (CLL). Reaching this milestone has released DKK 87m (USD 15.7m) to Genmab.

 

"This marks an important milestone, since this is the first Genmab antibody that has come onto the market in Europe," said Genmab's managing director Lisa Drakeman.

 

CLL is the most usual form of leukemia among adults. In the US around 90,000 people live with CLL and it is estimated that around 15,000 new cases are diagnosed each year. According to global estimates there were over 330,000 new cases of leukemia (all types) in 2007, and the disease was the cause of 245,000 deaths.

 

Link > Genmab                                          

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×